Allen-Hoffmann, who founded Stratatech in 2000 based on research in her UW-Madison lab, said it could take two years to begin the next phase of clinical trials. When that happens, StrataGraft also will be tested on pediatric burn patients.
Allen-Hoffmann, who founded Stratatech in 2000 based on research in her UW-Madison lab, said it could take two years to begin the next phase of clinical trials. When that happens, StrataGraft also will be tested on pediatric burn patients.